Literature DB >> 15971304

Epidemiological aspects of hadron therapy: a prospective nationwide study of the Austrian project MedAustron and the Austrian Society of Radiooncology (OEGRO).

Ramona Mayer1, Ulrike Mock, Robert Jäger, Richard Pötter, Christian Vutuc, Helmut Eiter, Kristine Krugmann, Josef Hammer, Brigitte Hirn, Robert Hawliczek, Tomas-Henrik Knocke-Abulesz, Peter Lukas, Elisabeth Nechville, Brigitte Pakisch, Michael Papauschek, Wolfgang Raunik, Walter Rhomberg, Hubert Sabitzer, Annemarie Schratter-Sehn, Felix Sedlmayer, Irene Wedrich, Thomas Auberger.   

Abstract

BACKGROUND: The planned MedAustron hadron therapy facility is designed to compare proton and carbon ion beam therapy under the same technical conditions. For the calculation of the number of potential patients for hadron therapy so far, only epidemiological estimations on cancer incidence are available without inclusion of the percentage of patients routinely referred to conventional radiotherapy.
MATERIALS AND METHODS: Nationwide prospective survey to collect disease and treatment related data on patients receiving conventional radiotherapy at all 12 treatment facilities. Epidemiological cancer incidence (Statistic Austria 1999) were correlated with the number of patients receiving conventional radiotherapy. Based on published clinical and experimental results on proton and carbon ion therapy, a calculation of patient's subgroups suitable for hadron therapy was performed at five European University hospitals involved in the HICAT, CNAO, ETOILE and MEDAustron project. Using the mean values of the University specific percentages per tumour site, the number of potential patients was estimated.
RESULTS: In Austria, a total of 3783 patients started radiotherapy during the study period of 3 months resulting in an approximated number of 15132 patients per year. The number of potential patients was estimated to 2044 per year, representing 5.6% of all newly diagnosed cancer patients and 13.5% of all irradiated cancer patients.
CONCLUSION: There is a clear place for a hadron therapy facility in Austria, based on pattern of care in radiotherapy, cancer incidence and indications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15971304     DOI: 10.1016/s0167-8140(04)80008-2

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  ENLIGHT and other EU-funded projects in hadron therapy.

Authors:  M Dosanjh; B Jones; R Mayer; R Meyer
Journal:  Br J Radiol       Date:  2010-10       Impact factor: 3.039

2.  Patients With Cancer in the Countries of South-East Europe (the Balkans) Region and Prospective of the Particle Therapy Center: South-East European International Institute for Sustainable Technologies (SEEIIST).

Authors:  Mimoza M Ristova; Vesna Gershan; Herwig Schopper; Ugo Amaldi; Manjit Dosanjh
Journal:  Adv Radiat Oncol       Date:  2021-08-09

3.  Proton therapy needs further technological development to fulfill the promise of becoming a superior treatment modality (compared to photon therapy).

Authors:  Daniel E Hyer; Xuanfeng Ding; Yi Rong
Journal:  J Appl Clin Med Phys       Date:  2021-11-03       Impact factor: 2.102

4.  Epidemiological study of the incidence of cancers eligible for proton or carbon ions therapy: methodology and results of recruitment estimation.

Authors:  Stéphanie Patin; Pascal Pommier; Hu Yi; Marie Hélène Baron; Jacques Balosso
Journal:  J Cancer Epidemiol       Date:  2013-06-20

5.  A Preliminary Study on the Estimation of the Number of Cancer Patients Eligible for Hadron Therapy in Iran and Fars Province.

Authors:  Mohammad Amin Hosseini; Mohammad Mohamadianpanah; Mohammad Zare-Bandeamiri; Mohammad Amin Mosleh-Shirazi
Journal:  Iran J Med Sci       Date:  2018-05

6.  Estimation of the medical need for carbon-ion radiotherapy in Korea.

Authors:  Ilsung Cho; Young Seok Seo; WonGyun Jung; Mi-Sook Kim
Journal:  J Radiat Res       Date:  2018-09-01       Impact factor: 2.724

7.  Estimating the Number of Patients Eligible for Carbon Ion Radiotherapy in the United States.

Authors:  Timothy D Malouff; Laura A Vallow; Danushka Seneviratne; Anita Mahajan; Robert L Foote; Bradford Hoppe; Chris Beltran; Steven J Buskirk; Sunil Krishnan; Daniel M Trifiletti
Journal:  Int J Part Ther       Date:  2020-11-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.